[SCHEDULE 13G/A] Cogent Biosciences, Inc. Amended Passive Investment Disclosure
Kynam Capital discloses 4.33% stake in Cogent
Kynam Capital Management and related reporting persons report beneficial ownership of 6,165,223 shares of Cogent Biosciences common stock, representing 4.33% of the class.
Kynam Capital Management and related reporting persons report beneficial ownership of 6,165,223 shares of Cogent Biosciences common stock, representing 4.33% of the class. The shares are held with shared voting and dispositive power and no sole authority.
The reporting persons are Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. They certify the position was acquired and is held in the ordinary course of business, without the purpose or effect of changing or influencing control of Cogent Biosciences.
Positive
None.
Negative
None.
FAQ
How many Cogent Biosciences (COGT) shares does Kynam Capital report owning?
Kynam Capital reports beneficial ownership of 6,165,223 Cogent Biosciences shares. These common shares are reported with shared voting and dispositive power among Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang in the Schedule 13G/A amendment.
What percentage of Cogent Biosciences (COGT) does Kynam Capital’s 6,165,223 shares represent?
The filing states that 6,165,223 shares represent 4.33% of Cogent’s common stock. This percentage reflects Kynam Capital’s reported beneficial ownership of the class as of the event date referenced in the Schedule 13G/A.
Who are the reporting persons in the Cogent Biosciences (COGT) Schedule 13G/A?
The reporting persons are Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. Each reports beneficial ownership of the same 6,165,223 Cogent Biosciences common shares with shared voting and dispositive power and no sole authority.
Does Kynam Capital have sole voting power over its Cogent Biosciences (COGT) shares?
No, the Schedule 13G/A shows zero shares with sole voting power. Instead, Kynam Capital Management, its general partner, and Yue Tang each report shared voting power over 6,165,223 Cogent Biosciences common shares, and shared dispositive power over the same amount.
What is the purpose of Kynam Capital’s Cogent Biosciences (COGT) holdings according to the filing?
The reporting persons certify the Cogent shares are held in the ordinary course of business. They state the securities were not acquired and are not held to change or influence control of Cogent, consistent with a passive investment stance under Schedule 13G.
What is the event date for Kynam Capital’s Cogent Biosciences (COGT) ownership reported here?
The Schedule 13G/A refers to an event date of 12/31/2025. Ownership figures, including the 6,165,223 Cogent Biosciences common shares and the 4.33% of the class, are reported as of that date triggering the amended beneficial ownership statement.
Kynam Capital Management, LP
Kynam Capital Management GP, LLC
Yue Tang
(b)
Address or principal business office or, if none, residence:
221 ELM ROAD
PRINCETON, New Jersey
08540
(c)
Citizenship:
Kynam Capital Management, LP - DELAWARE
Kynam Capital Management GP, LLC - DELAWARE
Yue Tang - UNITED STATES
(d)
Title of class of securities:
Common Stock, par value $0.001
(e)
CUSIP No.:
19240Q201
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
6,165,223
(b)
Percent of class:
4.33 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Kynam Capital Management, LP - 0
Kynam Capital Management GP, LLC - 0
Yue Tang - 0
(ii) Shared power to vote or to direct the vote:
Kynam Capital Management, LP - 6,165,223
Kynam Capital Management GP, LLC - 6,165,223
Yue Tang - 6,165,223
(iii) Sole power to dispose or to direct the disposition of:
Kynam Capital Management, LP - 0
Kynam Capital Management GP, LLC - 0
Yue Tang - 0
(iv) Shared power to dispose or to direct the disposition of:
Kynam Capital Management, LP - 6,165,223
Kynam Capital Management GP, LLC - 6,165,223
Yue Tang - 6,165,223
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
